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Pluripotent stem cells (PSCs) represent an appealing
source from which to develop cell replacement
therapies. Different initiatives have been launched
to promote their development toward clinical
applications. This article will review the main questions
that should be considered before translating PSC-derived
cardiomyocytes into clinical investigations, including
the development of good manufacturing practice-level
PSC lines, the development of efficient protocols to
generate pure populations of cardiac myocytes, and
the development of techniques to improve the
retention and survival rate of transplanted cells.embryonic stem cells (ESCs) were first isolated in 1998Different disorders, notably through myocardial ischemia,
can cause the critical loss of cardiomyocytes. This loss ini-
tiates a cascade of detrimental events, including the devel-
opment of cardiac fibrosis, formation of non-contractile
scar tissue and promotion of adverse ventricular remodel-
ing - all mechanisms that can lead to heart failure and
eventually death. Replacement of dead or dysfunctional
cardiac myocytes through cell-based therapies has thus
become an emerging and exciting strategy for the treat-
ment of heart failure.
The restoration of damaged heart muscle tissue can be
achieved through different strategies, including cell trans-
plantation approaches [1]. Even if recent evidence suggests
the existence of cardiomyocyte renewal in the post-natal
mammalian heart [2,3], the heart is one of the least regen-
erative organs in the body. Hence, a large number of
cardiac myocytes are needed for replacement therapy.* Correspondence: jean.hulot@mssm.edu
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© BioMed Central Ltd.2014However, human donor hearts and cardiomyocytes are in
extremely limited supply, motivating a demand for alterna-
tive cardiomyocyte sources. The remarkable proliferative
and differentiation capacity of stem cells represents an ap-
pealing strategy to provide an unlimited supply of specific
cell types, including viable functioning cardiac cells.
Different types of autologous cells (including skeletal
myoblasts, hematopoietic stem cells and mesenchymal
stem cells) have been tested so far in pre-clinical and clin-
ical trials but with inconsistent results [4-6]. In this review,
we specifically focus on the use of pluripotent stem cells
(PSCs) as a source for cell transplantation. PSCs have the
ability to differentiate into cell types of all three germ
layers, including cardiac and vascular cells [7-9]. Human
and are derived from the inner cell mass of blastocyst
stage embryos. They have the unique ability to self-renew
indefinitely while maintaining the potential to differentiate
into all cell types in the human body [10]. The use of hu-
man ESCs is, however, limited by different issues, includ-
ing ethical concerns. The revolutionary discovery of
induced pluripotent stem cells (iPSCs), whereby somatic
cells (such as dermal fibroblasts or white blood cells) can
be reprogrammed into an embryonic-like pluripotent state
by the forced expression of a defined set of transcription
factors [11], has provided another source of pluripotent
stem cells [12]. Like ESCs, iPSCs are multipotent and clo-
nogenic but can also offer autologous personalized ther-
apy. The seminal understanding of pluripotency holds
great promise for regenerative medicine and the use of
ESCs or iPSCs as a source for cardiac repair has thus be-
come an emerging and exciting field.
However, studies involving the transplantation of PSC-
derived cardiomyocytes into the heart have begun only
recently. There are currently a very limited number of
clinical studies using ESCs or iPSCs that have been ap-
proved [13]. In 2009, the Food and Drug Administration
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with spinal cord injury, but the trial was discontinued
due to funding challenges. PSCs are currently being
tested to treat patients with two different forms of
macular generation (Stargardt’s macular dystrophy and
age-related macular degeneration) using PSC-derived
retinal pigment epithelial cells [14]. A pilot clinical study
using iPSC-derived retinal pigment epithelium cells in
patients with exudative age-related macular degeneration
has been launched in Japan during summer 2013. It is
noteworthy that no clinical trials using PSC-derived car-
diomyocytes for the treatment of heart failure have been
approved so far, but different research programs have
been launched with the objective of treating patients
within the next 5 years. This article reviews the main
questions that should be considered before translating
PSC-derived cardiomyocytes into clinical investigations
(Figure 1).Generating good manufacturing practice and
clinical-grade pluripotent stem cell lines
Good manufacturing practice (GMP) criteria have been
established by both the European Medicines Agency and
the Food and Drug Administration to ensure optimally
defined quality and safety in cell transplantation studies.
The directive and guidelines are progressively evolving but
include requirements for cell therapy products, including


















Figure 1 Overview of the key issues to be addressed before therapie
can be translated into clinical investigations.and requires the development of standardized operating
procedures and quality control methodology for the entire
process from cell generation to storage of the cell therapy
products [16]. For example, appropriate safety testing will
be required for all animal-derived products. The use of
feeder-free derivation protocols and the development of
specific culture conditions that avoid xeno-components
but rather use GMP-quality human derivatives would be
preferable. Similarly, the generation of clinical-grade iPSCs
with the use of virus-free non-integrative reprogramming
techniques is probably desirable in the future. It is beyond
the scope of this review to detail all the requirements to
achieve a GMP-level cell product, but it is worth mention-
ing that the generation of clinical-grade PSCs is a critical
first step toward future applications [16]. Even though the
use of human ESCs and the derivation of iPSCs have be-
come very popular during the past years and have been
implemented in many research laboratories, the develop-
ment of GMP-grade PSCs will require significant effort
and resources that might be supported by a much smaller
number of laboratories.Defining the ideal level of differentiation
Different studies have clearly established that ESCs and
iPSCs can differentiate into myocytes with some struc-
tural and functional properties of cardiomyocytes [9,17].
The differentiation is, however, heterogeneous, raising
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ferentiated ESCs to form teratomas, an encapsulated
tumor that contains tissue components resembling nor-
mal derivatives of all three germ layers, when transplanted
into normal or diseased hearts has been reported by differ-
ent groups [18,19]. These concerns might even be stron-
ger for iPSCs, as reprogramming and in vitro culture of
these cells can induce genetic and epigenetic abnormal-
ities [20,21]. As a consequence, ESCs or iPSCs will require
some degree of pre-differentiation to restrict their differ-
entiation repertoire and prevent tumor growth. Significant
efforts are thus being made to optimize culture conditions
for the generation of cardiac-committed cells from PSCs.
Applying knowledge in developmental biology has guided
the development of most of these protocols. In vitro car-
diomyocyte differentiation mimics the process of cardio-
genesis in vivo. The generation of human PSC-derived
cardiomyocytes has primarily been performed through
embryoid body formation [22,23] but is highly increased
when human PSCs are exposed to activin A and bone
morphogenic protein 4 [24]. Different types of cardiomyo-
cytes, including atrial-, ventricular-, and nodal-like cells,
are formed, however, which might not be optimal for cell
transplantation purposes where highly homogenous popu-
lations of each cardiac subtype is desirable. The inhibition
of the Wnt signaling pathway in later stages of the differ-
entiation process has recently been associated with a
marked increase in the production of ventricular-like
cardiomyocytes [25,26].
Different cell sorting strategies based on surface
markers, differences in glucose and lactate metabolism or
labeling with some fluorescent dyes have also been pro-
posed to generate highly purified populations of PSC-
derived cardiomylocytes (up to 99% purity) [27-29]. Some
studies have suggested that even a low number of undif-
ferentiated cells might be sufficient to induce teratoma
formation [30]. Using these methods, the potential con-
tamination with undifferentiated cells should be kept
under the level of concern. Accordingly, several studies
found no teratomas in hearts transplanted with cardio-
myocytes or cardiac progenitors derived from purified
ESCs [17,31], suggesting the risk of tumor formation
might be quite low after appropriate cell preparation.
However, further analysis of the therapeutic potential of
PSCs and their progeny, including the risk of teratoma-
forming propensity in animal models with long-term fol-
low-up, is required before cell therapy with human PSCs
can advance to clinical trials.
Using the current techniques of differentiation, PSC-
derived cardiomyocytes appear to be less mature than
adult cardiomyocytes. Maturation of PSC-derived cardi-
omyocytes is, however, improved in the long term
(>80 days of in vitro differentiation and culture) [32] or
by inducing adult-like metabolism with specific medium[33]. However, whether more mature cells are preferable
for cell transplantation experiments remains unclear.
There is an intuitively attractive idea that the adult mam-
malian heart provides a 'cardiogenic environment' that will
drive maturation and orientation of cardiac myocytes from
pluripotent stem cells. Transplanted immature cells would
have the opportunity to further mature in vivo [34]. In
addition, the use of less differentiated but mesoderm-
committed PSC-derived cells might not only restore
myocardial tissue but could also contribute to revasculari-
zation. Further investigations are now needed to determine
the ideal level of differentiation for cell transplantation
using PSC-derived cardiomyocytes.Avoiding the rejection of transplanted cells
As transplanted PSC-derived cardiomyocytes might not
be of patient origin, the possibility of an immune response
must be addressed [35]. Transplant rejection is mainly
driven by allelic differences in the surface antigens
expressed by the donor and recipient. There are three dis-
tinct types of transplantation antigens: ABO blood group
antigens, minor histocompatibility antigens and major
histocompatibility complex (MHC) molecules. Allelic dif-
ferences in MHC molecules are, by far, the most signifi-
cant immunological barrier to organ transplantation.
Undifferentiated human ESCs are sometimes called 'immu-
noprivileged' because they express low levels of class I
MHC (MHC-I) molecules [36-38]. However, MHC-I ex-
pression increases approximately 10-fold with the induction
of differentiation [38]. Stem cell graft rejection may be trig-
gered when the recipients’ allogeneic T cells recognize the
foreign MHC-I surface molecules, whether differentiation
occurs before or after transplantation. A number of
methods have been proposed to address immunorejection
[39]. Among them, derivation of ESCs that have their
MHC (also called human leukocyte antigen (HLA) in
humans) matched with the patient’s could be a potential
method for minimizing immunorejection in ESC trans-
plantation [40,41]. In contrast with ESCs, the development
of iPSC-derived differentiated cells has been expected to
provide personalized sources for cell-based therapy. How-
ever, the overall time to generate, expand and characterize
patient-specific iPSCs creates an important barrier to the
development of such personalized approaches. Moreover,
iPSCs were originally believed to be non-immunogenic
but recent data have raised concerns about the potential
immunogenicity of these cells. A recent study reported
that the transplantation of immature iPSCs induced a
T-cell-dependent immune response even in a syngeneic
mouse, likely due to abnormal gene expression [42]. This
immunogenicity could be linked to the over-expression of
minor antigens potentially resulting from point mutations
in the coding sequences of iPSCs [20] or the epigenetic
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not confirmed in two subsequent studies [44,45].
One strategy to address this issue and avoid the use of
intensive immunosuppressive agents is to create a collec-
tion of PSCs with distinct MHCs that will match the ma-
jority of the general population. It has, for instance, been
reported that the generation of 50 iPSC lines would be
sufficient to cover 90% of the Japanese population [46].
The panels of HLA types would, however, be higher in
populations with high genetic diversity, thus requiring the
generation of a higher number of iPSC lines. These HLA-
organized banks of PSCs would certainly help to limit the
risk of rejection but might not eradicate the immunogenic
risk because of the limited number of HLA-compatible
loci and the level of HLA typing resolution [47].
Ensuring the survival and the engraftment of
transplanted cells
The survival and integration of transplanted cells into
the host is a critical challenge. The first evidence that
ESC-based therapies can engraft and form myocardium
in vivo came from small animal models where human
ESC-based therapies were directly injected into the nor-
mal myocardium [48]. Further experiments were then
performed in diseased conditions, especially in ischemic
hearts. While in animal models the number of cells and
injections may vary, the common concept is to deliver
cells in or around the infarcted myocardium. Most of
these studies have shown that the grafted PSC-derived
cardiomyocytes are mainly found as confluent cell clus-
ters in the infarct border zone [17,18]. Further investiga-
tions showed that left ventricular (LV) contractile
function was improved (or at least its worsening was
prevented) in treated animals compared to non-treated
animals. However, extensive data indicate that most cells
that were transplanted into the heart do not survive
long-term. Cell retention and survival are consistently
low when injected into the myocardium, and even lower
with intracoronary infusion [17,49,50]. These data are
also consistent with the results derived from clinical tri-
als that have transferred different types of autologous
cells (including skeletal myoblasts, hematopoietic stem
cells and mesenchymal stem cells) into the human myo-
cardium [4-6], which generally came to the conclusion
that these cells do not form a significant amount of new
myocardium over the long term. Several challenges need
to be addressed to improve cell engraftment, retention
and survival. As an example, a challenge relates to the
orientation of transplanted cells in the heart architec-
ture. The alignment of transplanted cells with the host
myocardium would enhance the force generation. In
addition, it is generally unclear if cell transplantation is
associated with the development of an efficient blood
flow to supply the transplanted cells.Most of the pre-clinical experiments investigating PSC-
based therapies were performed in small animal models,
which might not be the most appropriate for clinical dis-
ease scenarios. The development of electromechanical
junctions between transplanted cells and the surrounding
host cardiomyocytes is required for synchronous contrac-
tion. However, it is likely that human ESC- or iPSCs-
derived cardiomyocytes have difficulties coupling to
rodent host myocardium because human cells cannot
keep up with a rodent’s high heart rate. Although electro-
mechanical coupling of human ESC-derived cardiomyo-
cytes with host cells has been reported in guinea pigs [51],
it has potentially been underestimated. Therefore, the use
of large animal models for testing human-derived cardiac
stem cell therapies is preferred. Large animal models do,
however, have limitations, including the requirement of
larger numbers of cells, the development of suitable im-
munosuppression protocols and higher costs. Different
groups have reported the administration of PSC-derived
therapies in pigs and monkeys [18,52,53]. ESC-derived
cardiovascular progenitors (selected on the SSEA-1 cell
surface marker) have been investigated in a Rhesus
monkey model of myocardial infarction [18] created by a
90-minute coronary occlusion/reperfusion protocol; the
selected cells were injected 2 weeks later in the infarcted
area during open-chest surgery. These cells engrafted into
the infarcted monkey hearts and differentiated into mor-
phologically mature cardiomyocytes. In a recent study,
Xiong and colleagues [53] reported the administration of
iPSC-derived vascular cells in a swine model of myocardial
infarction. The transplanted cells were engineered to ex-
press a fluorescent reporter (green fluorescent protein)
and the engraftment rate was estimated to be about 7%
after 1 week and about 2% after 4 weeks. Altogether, these
studies suggest that improving cell survival over the long
term is critical before considering future clinical applica-
tions [54].
Defining the optimal delivery route to the
myocardium
An alternative approach to direct cell injection is to cre-
ate a tissue-engineered version of cardiac muscle from
human ESCs and iPSCs. In recent publications [55-57],
it has been shown that the ex vivo combination of ESCs/
iPSCs with polymeric scaffolds allows the generation of
tissue-engineered muscle constructs. The engineered tis-
sues show coherent contractions 5 to 10 days after cast-
ing. They display a dense network of longitudinally
oriented, interconnected and cross-striated cardiomyo-
cytes, suggesting that the three-dimensional tissue for-
mat improves the maturation of cardiomyocytes [55]. It
has been suggested that a geometrically straight struc-
ture of the tissue and cyclic strain favor cardiomyocyte
maturation [55]. In an early study, human bioengineered
Note: This article is part of a thematic series on Cardiovascular
regeneration edited by Ronald Li. Other articles in the series can
be found online at http://stemcellres.com/series/cardiovascular.
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healthy athymic rat heart, showing graft survival and con-
nection to the host myocardium and coronary circulation
[56]. In another study [58], a composite construct made of
adipose tissue-derived stromal cells and ESC-derived car-
diac progenitors was applied surgically in monkeys that
underwent myocardial infarction. Two months later, the
progenitors had differentiated into cardiomyocytes and
there was robust engraftment of the donor tissue associ-
ated with increased angiogenesis [58]. These data suggest
that in vivo engraftment of engineered cardiac tissues cre-
ated from ESC- or iPSC-derived cardiomyocytes repre-
sents an interesting alternative strategy to direct cell
injection therapy. In addition to further investigations in
pre-clinical models, the use of GMP-level materials would,
however, be required for future clinical applications.
Analyzing the appropriate endpoints post-
delivery
Studies evaluating stem cell-based therapies in vivo have
primarily focused on the changes in LV function and in
cardiovascular outcomes. The study methology, sample
size, type of cells and route of administration typically dif-
fer between these studies, but most have evaluated the
changes in LV ejection fraction as a surrogate of the bene-
fit of stem-cell based therapies. The primary assumption
is that the transplanted cells will directly replace the failing
tissue and contribute to cardiac contraction, and that the
higher the number of cells being engrafted the more the
ejection fraction will be increased. There is, however, a
large controversy on the mechanisms by which stem cell-
based therapies contribute to improving cardiac function
[1]. In addition or in place of direct action on contraction,
it is plausible that paracrine effects or changes in the myo-
cardial response to injury have an important contribution.
In a recent study investigating the functional conse-
quences of human iPSC administration in a swine model
of myocardial infarction [53], it was found that iPSC trans-
plantation mobilizes endogenous progenitor cells in the
heart, thus reducing LV remodeling. Even if the factors se-
creted or released from injected cells remain to be fully
characterized, the 'paracrine concept' has become very
popular among the scientific community.
As a consequence, one of the major objectives will now
be to correlate cell engraftment with improvements in
local and global cardiac function as well as improvements
in morbidity and mortality. Several strategies has been
proposed to track the fate of the transplanted cells, includ-
ing genome editing for molecular imaging [59] and mag-
netic resonance imaging-based reporter gene technology
[60]. Magnetic resonance imaging cell tracking is particu-
larly appealing in cardiology as it would allow a simultan-
eous assessment of cell engraftment and cardiac function.
This can be achieved through genomic engineering of thetransplanted cells or labeling these cells with super-para-
magnetic iron oxide particles. These labeled cells might,
however, only be compatible with pre-clinical studies. In a
recent study conducted in 110 patients with dilated car-
diomyopathy, cell homing of administered CD34+ cells
was investigated by labeling a fraction of the cells with
99mTc-hexamethylpropylenamine and performing single-
photon emission computed tomography imaging 2 and
18 hours after the intracoronary delivery [61]. The average
cell retention rate was 5% at 18 hours after injection but
correlated well with functional outcomes at 3 and
12 months, those patients with above-average cell reten-
tion demonstrating a significant increase in LV ejection
fraction. This study clearly paves the way for the design of
a new generation of clinical cell therapy trials [62]. In
these studies numerous parameters would be recorded, in-
cluding cell homing and localization, global cardiac func-
tion, hemodynamic parameters and also cardiac volumes
and dimensions. The rise of multimodality imaging
(including in small animals) provides opportunities to
measure global cardiac function parameters (such as LV
ejection fraction and LV volumes) and local changes in
cardiac fibrosis, scar areas or perfusion markers. Further-
more, this array of parameters could be measured at early
and late time points after transplantation to more compre-
hensively evaluate the full impact of PSC-based therapies.
Finally, it has been suggested that transplanted cells
can rapidly diffuse from the heart to other organs (that
is, lungs, liver, kidneys, spleen) [63]. Whether this
phenomenon exists with PSC-derived cardiomyocytes
remains to be determined. However, as for any experi-
mental drug, appropriate biodistribution and toxicology
studies will need to be performed in animal models
before moving into clinical investigations.
Conclusion
PSCs represent an appealing cell type for developing cell
replacement therapies. Different initiatives have been
launched to promote their development toward clinical
applications. However, ESC/iPSC technologies have sev-
eral specific issues that remain to be overcome, including
the development of GMP-level PSC lines, the develop-
ment of efficient protocols to generate pure populations
of cardiomyocytes, and the development of techniques to
improve the retention and survival rate of transplanted
cells. Once these are overcome, the first clinical trials will
then be on the horizon.
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